Breaking News

CMC Bio Licenses Expression System to OBT

Oxford Biotherapeutics to use cell system for oncologic therapeutic antibody production

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CMC Biologics and Oxford BioTherapeutics (OBT) entered into a non-exclusive license agreement providing OBT with access to CMC Biologics’ CHEF1 expression system for R&D and commercial use. CMC’s CHEF1 cell line development platform is designed to promote high-level expression of recombinant proteins early in development to allow for rapid isolation of cell lines. OBT plans to use the CHEF1 system for the production of its oncologic therapeutic antibodies. Financial terms were no...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters